Drug Trial Radar · NCT03257098
Allogeneic ABCB5-positive Stem Cells for Treatment of CVU
Last checked: Nov 20, 2026Latest source record: Sep 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Nov 16, 2017
Primary completion
Jun 25, 2020
Study completion Jun 25, 2020
Sponsor
- Lead sponsor
- RHEACELL GmbH & Co. KGIndustry
- Sponsor type
- Industry
- Collaborators
- FGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & Services
- First posted
- Aug 22, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of Chronic Venous Ulcers) and safety (by monitoring adverse events) of the medicinal product to be studied after two applications on the wound surface in patients with Chronic Venous Ulcers.
Conditions
- Skin Ulcer Venous Stasis Chronic
Interventions
allo-APZ2-CVUBiological
Suspension of ABCB5-positive mesenchymal stem cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of wound size reductionTime frame: Week 12 post baseline, or last available post-baseline measurement if the Week 12 measurement is missing
- Assessment of adverse event (AE) occurrenceTime frame: Up to 12 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Venenzentrum der Dermatologischen und Gefäßchirurgischen Kliniken, Kliniken der Ruhr-Universität Bochum im St. Maria Hilf Krankenhaus
Bochum, Germany
Universitätsklinikum Erlangen, Hautklinik
Erlangen, Germany
Klinik und Poliklinik für Hautkrankheiten, Universitätsmedizin Greifswald
Greifswald, Germany
Klinische Forschung Hamburg GmbH, Dermatologie / Allergologie
Hamburg, Germany
pro scientia med im Mare Klinikum; Department Klinische Forschung und Entwicklung
Kiel, Germany
Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie
Münster, Germany
Klinische Forschung Schwerin GmbH
Schwerin, Germany
Universitätsklinikum Ulm, Klinik für Dermatologie und Allergologie
Ulm, Germany
Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg
Würzburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.